In Alzheimer’s disease, laduviglusib has been associated with decreased tau phosphorylation in human glutamatergic neurons, suggesting its capacity to counteract tau pathology, particularly in neurons [13]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.